Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: software salesperson who wrote (2568)	4/27/2008 3:37:55 PM
From: Biotech Jim	Respond to of 3158

SS- There is an interesting/challenging hurdle for these types of trials where the exists a broad-based standard of care. RA appears to be such a case, where methotrexate MTX is the standard of care (like in T2DM where metformin is the std of care). In my view, the current focus in MTX patients is appropriate, as it might be considered unethical to not have a pt on MTX. Dr. Weinblatt established this as the std, and he was involved in the RIGL CC and trial. I do not make a big deal about potential side effect rate differences of cmpds/mAbs in PA vs RA, unless dramatic, as to my knowledge there have not been side-by-side trials using similar sites. I might expect toxicities to be similar unless different aged populations. Upon reflection on the RIGL data, I am now more bullish on the utility of 788 in RA. Do not hold a position though. BJ